# US 2012/0253017 A1 · Stem cell targeting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253017 A1
- Document ID: US20120253017A1
- Status: Published application
- Kind: A1
- Application number: 13/322,030
- Filed: 2010-05-26
- Published: 2012-10-04
- Earliest claimed: 2009-05-28
- Inventors: Victoria Ballard; Thil Dinuk Batuwangala; Edward Coulstock; Elena De Angelis; Jay Edelberg; Carolyn Enever; Steve Holmes; Zahra Ja wad-Alami
- Web page: https://patentgrep.com/patent/US20120253017A1

## CPC

- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/195: {Chemokines, e.g. RANTES}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention describes a construct wherein the tissue specific marker is a muscle specific marker molecule. Such a construct may be used in a pharmaceutical composition for use in muscle regeneration or heart disease.

## Claims

### Claim 1

An antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule.

### Claim 2 (depends on 1)

The construct as claimed in claim 1 wherein the tissue specific marker is a muscle specific marker molecule.

### Claim 3 (depends on 2)

The construct as claimed in claim 2 wherein the tissue specific marker is a myocardium-specific marker molecule.

### Claim 4 (depends on 1)

The construct as claimed in any of claim 1 wherein the first or second agent is a monoclonal antibody.

### Claim 5 (depends on 1)

The construct as claimed in any of claim 1 wherein the first or second agent is an epitope-binding domain.

### Claim 6

The construct as claimed 5 wherein the epitope-binding domain is an immunoglobulin single variable domain.

### Claim 7 (depends on 1)

The construct as claimed in any of claim 1 wherein the stem cell specific marker molecule and the tissue specific marker molecule are human.

### Claim 8 (depends on 1)

The construct as claimed in any of claim 1 wherein the stem cell specific marker molecule is c-Kit.

### Claim 9 (depends on 1)

The construct as claimed in any of claim 1 wherein the muscle-specific marker molecule is selected from the group consisting of a myosin-derived molecule such as Myosin Light Chain (MLC), cardiac myosin, human ventricular myosin light chain 1 (vMLC1), MLC 1, MLC 2 and MLC 3, cardiac troponin I, cardiac troponin, Tenascin C or creatine kinase.

### Claim 10 (depends on 9)

The construct as claimed in claim 9 wherein the agent which binds to a muscle specific marker molecule is an anti-MLC antibody.

### Claim 11 (depends on 10)

The construct as claimed in claim 10 wherein the anti-MLC antibody is a monoclonal antibody available from ATCC HB 11709.

### Claim 12 (depends on 1)

The construct as claimed in claim 1 wherein the first agent is an anti-c-Kit monoclonal antibody and the second agent is an anti-MLC monoclonal antibody.

### Claim 13 (depends on 1)

The construct as claimed in any of claim 1 which is a MAbdAb.

### Claim 14 (depends on 13)

The construct as claimed in claim 13 wherein the first agent is an anti-c-Kit immunoglobulin single variable domain and the second agent is a monoclonal anti-MLC antibody.

### Claim 15 (depends on 8)

The construct in any of claim 8 wherein the epitope binding domain which binds c-Kit is an immunoglobulin single variable domain or polypeptide.

### Claim 16 (depends on 8)

The construct in any of claim 8 wherein the epitope binding domain which binds c-Kit is an immunoglobulin single variable domain or polypeptide having an amino acid as set out in any of SEQ ID NOs: 302-305, 457, 458 or 482.

### Claim 17 (depends on 9)

The construct as claimed in claim 9 wherein the anti-MLC antibody is an antigen binding protein or antibody which binds human ventricular myosin light chain 1 (vMLC1).

### Claim 18 (depends on 1)

The construct as claimed in claim 1 wherein the first agent and second agent are linked.

### Claim 19 (depends on 15)

The construct as claimed in claim 15 wherein the linker is selected from any one of: A G4S linker (GGGGS); TVAAPS; ASTKGPT; ASTKGPS; EPKSCDKTHTCPPCP; ELQLEESCAEAQDGELDG, AST, STGGGGGS, STGGGGGSGGGGS, STGPPPPPS, STGPPPPPPPPPPS, STG, PPPPPS, STGSRDPYLWSAPSDPLELVVTGTSVTPSRLPTEPPSSVAEFSEATAELTVSFTNKVFT TETSRSITTSPKESDSPAGPARQYYTKGNGSTG, ‘STG’ (serine, threonine, glycine), ‘GSTG’ or ‘RS’.

### Claim 20 (depends on 13)

A construct as claimed in claim 13 wherein the construct is selected from any of the constructs described in Table 24.

### Claim at position 21

21-81. (canceled)
